The Avastin (Bevacizumab) biosimilars market size was valued at USD 4.5 billion in 2022 and is projected to reach USD 13.8 billion by 2030, growing at a CAGR of 15.1% from 2024 to 2030. The increasing adoption of biosimilars across oncology treatments, alongside the patent expiration of the original drug, has significantly driven market growth. These factors are expected to sustain demand for more affordable and accessible cancer therapies in both developed and emerging markets, contributing to the market's rapid expansion in the forecast period.
As the biosimilar landscape for Avastin continues to evolve, the shift toward these cost-effective alternatives is anticipated to intensify. Market opportunities are also expected to rise with a growing focus on clinical evidence and approval of new biosimilar products. By 2030, the Avastin biosimilars market is set to become a substantial portion of the global oncology therapeutics market, driven by favorable regulatory policies, improved healthcare accessibility, and rising awareness regarding biosimilars' efficacy and safety profile.
Download Full PDF Sample Copy of Market Report @
Avastin (Bevacizumab) Biosimilars Market Research Sample Report
The Avastin (Bevacizumab) biosimilars market by application encompasses a wide range of therapeutic settings where these biosimilars are administered. Avastin biosimilars are primarily used for the treatment of various cancers, including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, glioblastoma, and others. By leveraging similar mechanisms to the original Avastin, these biosimilars work by inhibiting vascular endothelial growth factor (VEGF), which is responsible for tumor angiogenesis. The use of Avastin biosimilars has grown significantly, as they offer a more cost-effective alternative while maintaining comparable efficacy and safety profiles. This makes them a viable option in both developed and emerging markets, where cost reduction is a priority for healthcare systems and patients alike.
As healthcare systems strive to manage costs while ensuring access to life-saving treatments, the availability of Avastin biosimilars plays a key role in oncology care. The market dynamics are significantly influenced by government regulations, pricing policies, and reimbursement schemes. Many countries have recognized the therapeutic benefits of Avastin biosimilars and have included them in national healthcare formularies. Moreover, the expanding number of biosimilar manufacturers and their increasing approval rates are contributing to a growing market for Avastin biosimilars across different therapeutic areas. Furthermore, Avastin biosimilars have shown efficacy in non-oncology applications as well, such as ophthalmologic treatments, which further expands the market scope and its potential for growth.
The hospitals subsegment plays a critical role in the Avastin (Bevacizumab) biosimilars market, as most of the administration of these treatments takes place within the hospital setting. Hospitals are equipped with the necessary infrastructure, skilled professionals, and monitoring capabilities to administer complex therapies like Avastin biosimilars to patients, particularly those with severe conditions such as cancer. This subsegment is expected to hold a significant share of the biosimilars market due to the advanced medical care provided in hospitals. In addition to providing infusion treatments, hospitals are also central to clinical trials and research studies that assess the safety and efficacy of Avastin biosimilars in diverse patient populations.
Hospitals are particularly essential for the management of patients undergoing Avastin biosimilar treatments, where multi-disciplinary care is often required, especially in oncology departments. The availability of trained oncologists, nurses, and pharmacists ensures that Avastin biosimilars are administered in accordance with the latest treatment guidelines, which helps optimize therapeutic outcomes. Furthermore, hospital-based oncology centers are also integral to the post-treatment care and monitoring of patients for potential side effects and complications. Given the increasing demand for cancer therapies, hospitals remain key to the successful implementation and uptake of Avastin biosimilars in clinical practice.
Clinics serve as another important subsegment within the Avastin (Bevacizumab) biosimilars market, offering an accessible point of care for patients requiring outpatient treatments. Clinics are increasingly adopting biosimilar therapies due to the lower costs compared to their reference biologics, and this trend is expected to continue as more biosimilars gain regulatory approval. The use of Avastin biosimilars in clinical settings offers a more convenient treatment option for patients, as it reduces the need for extended hospital stays while still delivering effective outcomes for conditions such as colorectal cancer, lung cancer, and others. This accessibility is an attractive feature for both patients and healthcare providers, particularly in the management of chronic conditions.
Clinics are also expanding their role in delivering Avastin biosimilars for non-oncological indications, such as ophthalmic treatments for conditions like age-related macular degeneration (AMD). With advances in biosimilar formulations and delivery systems, clinics are well-positioned to provide continuous care for patients, ensuring both affordability and effective treatment. As the adoption of biosimilars increases across a broader range of medical specialties, clinics stand to gain more market share in the biosimilars landscape, reinforcing their importance in providing high-quality, cost-effective healthcare services.
The "Others" subsegment includes a variety of healthcare settings that play a role in the administration of Avastin (Bevacizumab) biosimilars but do not fall strictly under hospitals or clinics. This category may include home healthcare services, specialized outpatient centers, and ambulatory care centers, among others. For instance, in-home healthcare services are becoming increasingly popular as patients and caregivers look for convenient, patient-centered options for cancer treatment. Avastin biosimilars, particularly those used in long-term treatment regimens, can be administered in this setting with the help of trained professionals, ensuring patient comfort and continuity of care. This growing trend for home-based care services creates an additional opportunity for the distribution and use of Avastin biosimilars.
Specialized outpatient centers, such as cancer treatment centers, are another component of the "Others" subsegment. These centers are equipped to provide advanced oncology care, including the administration of Avastin biosimilars, typically in a more personalized manner. The growing number of such facilities worldwide, combined with increased awareness of the cost-effectiveness of biosimilars, is driving demand for Avastin biosimilars outside traditional hospital settings. As the healthcare landscape continues to evolve toward more flexible and patient-centric models, the "Others" subsegment will continue to play a pivotal role in the expansion of the Avastin biosimilars market.
One of the key trends in the Avastin (Bevacizumab) biosimilars market is the rising acceptance of biosimilars as a viable alternative to reference biologics. As more biosimilars gain regulatory approval, particularly in major markets such as the United States and the European Union, healthcare providers are increasingly willing to adopt them as part of standard treatment protocols. This trend is supported by robust clinical data demonstrating comparable efficacy and safety between Avastin and its biosimilars. Additionally, the growing pressure on healthcare systems to reduce costs without compromising treatment quality is driving the adoption of biosimilars, providing significant opportunities for market growth.
Another major trend is the expanding indications for Avastin biosimilars beyond oncology. While the majority of Avastin biosimilars are used in cancer treatment, there is a growing focus on their use in ophthalmic conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. This broader application opens up additional revenue streams for biosimilar manufacturers, and as the technology behind biosimilars advances, new indications for these therapies are expected to emerge. The growing focus on patient-centric care, as well as the increasing availability of home and outpatient care options, further enhances the prospects for Avastin biosimilars in a variety of settings, creating new opportunities for industry players to explore.
What are Avastin biosimilars?
Avastin biosimilars are biologic drugs designed to be highly similar to the reference biologic Avastin, used primarily for cancer and ophthalmic treatments.
How do Avastin biosimilars work?
These biosimilars work by inhibiting vascular endothelial growth factor (VEGF), which prevents the formation of blood vessels that support tumor growth.
Why are Avastin biosimilars important in healthcare?
They offer a cost-effective alternative to the original Avastin, helping to reduce healthcare costs while maintaining treatment efficacy.
What are the major applications of Avastin biosimilars?
Avastin biosimilars are mainly used in oncology, for cancers like colorectal cancer, lung cancer, and glioblastoma, as well as for ophthalmic conditions like macular degeneration.
How do hospitals use Avastin biosimilars?
Hospitals administer Avastin biosimilars in controlled environments to treat cancer patients, often as part of comprehensive treatment plans.
Can Avastin biosimilars be used in clinics?
Yes, clinics are increasingly using Avastin biosimilars for outpatient treatment, offering a cost-effective alternative to the reference biologic.
What are the advantages of Avastin biosimilars over reference biologics?
The main advantage is cost savings, as biosimilars are typically priced lower than the original drug while offering similar efficacy and safety.
Are Avastin biosimilars approved by regulatory authorities?
Yes, Avastin biosimilars have been approved by regulatory agencies like the FDA and EMA following rigorous clinical trials and assessments.
How do Avastin biosimilars compare to other biosimilars in the market?
Avastin biosimilars are among the most widely used in oncology, with proven efficacy and safety profiles that position them as leaders in the biosimilars space.
What is the future outlook for Avastin biosimilars?
The market for Avastin biosimilars is expected to grow as more approvals are granted, and demand for affordable cancer and ophthalmic treatments increases.
For More Information or Query, Visit @ Avastin (Bevacizumab) Biosimilars Market Size And Forecast 2025-2030